








Genotypes at the APOE and SCA2 loci do not predict the course of
multiple sclerosis in patients of Portuguese origin
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Multiple sclerosis (MS) is a demyelinating disease that affects about one in 500 young Europeans. In order to test the previously proposed
influence of the APOE and SCA2 loci on susceptibility to MS, we studied these loci in 243 Portuguese patients and 192 healthy controls
and both parents of 92 patients. We did not detect any significant difference when APOE and SCA2 allele frequencies of cases and
controls were compared, or when we compared cases with different forms of the disease. Disequilibrium of transmission was tested for
both loci in the 92 trios, and we did not observe segregation distortion. To test the influence of the APOE o4 and SCA2 22 CAGs alleles
on severity of disease, we compared age at onset and progression rate between groups with and without those alleles. We did not
observe an association of the o4 or the 22 CAGs alleles with rate of progression in our total patient population; allele o4 was associated
with increased rate of progression of MS in a subset of patients with less than 10 years of the disease. However, globally in the Portuguese
population, the APOE and SCA2 genes do not seem to be useful in the clinical context as prognostic markers of this disorder.
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Introduction
Multiple sclerosis (MS) is a chronic primary demyelinat-
ing disease of the central nervous system (CNS) affecting
one in 500 young Europeans. It is characterized by a wide
range of clinical manifestations and classified in re-
lapsing/remitting, primary progressive, secondary pro-
gressive, and benign forms.1
The higher concordance rate of MS in monozygotic
twins (25%) versus dizygotic twins (3%)24 strongly
suggests that genetic factors are involved in the aetiology
of this disorder; however, the number and type of genes
involved and their mechanisms remain uncertain. In the
interaction between susceptibility genes and environmen-
tal factors, none seem sufficient by itself to cause the
disease.1 Moreover, while some genes may be involved in
the induction of the disease, others may have a role in its
progression.5
Although several chromosomal regions have been pro-
posed as possible locations of susceptibility genes, the
MHC class II on chromosome 6 is the only consistent one:
only the DR15 allele association, in northern Europeans,6
and the association with DR4 in Sardinians,7 have been
reproducible. In the UK, regions 3p21-p14, 5q14-q15,
6p21, 7p21-p15, 17q22-q24, 19q13 and Xp21-p11 have
also been proposed.8,9 Other regions were suggested by the
Canadian study (2p16, 3p14-p12, 3q21-q25, 5q14-q15,
6p21, 7p21-p15, 7q21-q22, 19q13 and Xp21-Xp11),10 the
study of the Multiple Sclerosis Genetics Group (2p16,
3q21-q25, 5q14-q15, 6p21, 7q11-q22 and 19q13)11 and by
the Finnish group (3q21-q25, 6p21, 17q22-q24 and
19q13).12 Regions overlapping among all these are 3q21-
25, 6p21 and 19q13. Whole genome screens for linkage
disequilibrium in MS published by the UK13 and Ger-
man14 groups suggested several interesting regions for MS
susceptibility loci. Overlapping genomic regions between
these two studies are on chromosomes 1p, 1q, 6p (HLA
region), 17q and 19q.
The APOE and SCA2 genes are involved in other
neurodegenerative diseases and previous studies sug-
gested they may play a role in susceptibility to MS. The
SCA2 gene, when containing a CAG repeat above 36 units
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in the coding region, causes an autosomal dominant
spinocerebellar ataxia (SCA2).15 17 It has been reported
that the 22 CAG allele segregates preferentially with MS,18
either due to a direct effect or to that of a gene in linkage
disequilibrium with this locus.
Apolipoprotein E (ApoE) is a 34 kDa protein involved in
cholesterol metabolism, lipid transport and in neuronal
development and regeneration.19 The APOE gene has
three main alleles, o3 being the most frequent.2022 The
ApoE o4 isoform has a higher affinity to bind lipid
molecules,23 and has been associated with a higher risk
of Alzheimer’s disease24,25 and cardiovascular dis-
ease,26,27 but also with a worse outcome in MS;28 32 this
could be related to a lower capacity of repair (remyelina-
tion of lesions) or to a protection against axonal degenera-
tion consecutive to these lesions. The APOE gene has
been implicated as a susceptibility risk factor29 and as
affecting the progression of disability in MS.28,3032 We
have now tested the hypotheses 1) that the APOE and
SCA2 loci may have a role in the susceptibility to MS, and
2) that specific alleles in these loci may correlate with
severity and progression in the Portuguese population.
Material and methods
Subjects
We studied a sample of 243 unrelated patients (mean
age/38.39/10.8 years; 170 females, 73 males) of Portu-
guese origin collected in different regions of the country,
with definite diagnosis of MS according to the criteria of
Poser et al.33 The disease was classified as primary
progressive (PP; n/34) or other forms of the disease
(OF; n/184), of which 72.8% were with recurrences and
remissions, 12.0% secondary progressive, 2.7% optical
nevritis, 1.1% benign and 11.4% undefined (patients for
whom it was impossible for the neurologist to clearly
classify the disease course); for 25 cases we had no
information about the form of the disease. Values of
Expanded Disability Status Scale (EDSS), ranging from 0
(no impairment) to 10 (death from MS),34 were obtained
for 140 patients; 85.7% of these patients were undergoing
b-interferon therapy. The progression index (PI)35 gives a
measure of increase in disability through time and is
calculated by dividing the EDSS by disease duration in
years. Both parents of 92 patients were also studied. We
also studied 192 unrelated healthy controls (HC) (all
excluded for MS by a neurologist) matched to the case
by gender, age (9/2 years) and region of origin. Written
informed consent was obtained from all subjects.
Methods
Genomic DNA from all subjects was isolated from periph-
eral blood using the Gentra system (PuregeneTM). The
APOE genotyping was performed by PCR-RFLP,36 in an
8% nondenaturing polyacrilamide gel, using Hha I. The
size of the (CAG)n at the SCA2 locus was determined by
PCR, as described;16 PCR products (separated in a 6%




Frequency of risk genotypes, i.e., at least one risk allele (o4
for the APOE gene and homozygosity for the 22 allele for
the SCA2 gene) was compared between cases and con-
trols, using the McNemar test. This was also used to
compare frequencies of risk genotypes in patients and
individually matched controls, for each clinical subgroup
(PP or OF). Fisher’s exact test was used to compare
genotypes of cases with PP versus OF of MS. Disequili-
brium of transmission was tested with the TDT-STDT
program (v.1.1) in the 92 trios. To compare patients
concerning clinical variables, and to test for differences
between patient subgroups with a specific genotype,
Student’s t -test and Mann/Whitney tests were performed
(Table 1).
Results
No significant differences were found between patient
subgroups with a specific genotype with regard to the
patients’ mean age, disease duration and gender distribu-
tion (data not shown); we concluded these would not be
confounding factors for the remaining analyses.
We found no significant differences when cases and
controls were compared regarding the presence/absence of
the allele o4 of the APOE gene (P/1.0) and homozygosity
for the 22 CAGs allele at the SCA2 locus (P/0.752) (Table
2). Comparison of genotype frequencies for the APOE and
SCA2 genes, between cases with PP versus OF disease,
and between each of these subgroups with matched
controls, did not reveal any significant differences (Figure
1a and b). We also did not detect transmission disequili-
brium for any allele at either loci in the 92 trios studied
(data not shown).
We did not detect an influence of the risk genotypes on
the severity of the disease, measured through the EDSS
and PI values in the total sample. However, patients with a
duration of disease less than 10 years and carrying the
APOE o4 allele (n/8) presented a faster progression than
those not carrying this allele (n/61) (PI: 0.809/0.5 and
0.499/0.4, respectively; P/0.026) (Table 1).
Discussion
The European population is highly heterogeneous: genetic
differences occur across relatively small distances and
genetic clines for some markers of susceptibility to MS
already identified also appear to correlate with distribu-
tion of the disease.1 Different genetic backgrounds and
environments, which could be interacting among them,
may cause susceptibility to MS in different populations or
even within the same population. Genes that play a role in
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susceptibility to MS in given populations may not have
the same role in others.5 It is thus important that studies
be replicated in other population, and even with different
samples within the same population.
Our study on Portuguese MS patients could not confirm
the previously reported influence of the APOE gene on
susceptibility to this disease,29 which has also been
excluded in various studies in other popula-
tions,28,31,32,37 40 including linkage studies in a Finnish
population, which suggested that 19q13.2-q13.3, where
the gene APOE is localized, was not a candidate region for
susceptibility to MS.41 The 22 CAGs SCA2 alleles did not
seem to segregate preferentially with MS in our sample, as
had been reported in patients from the UK.18 Our data are
in agreement with later studies in a Dutch population.42
Therefore, neither of these two loci could be related to
susceptibility to MS in Portuguese patients; this was
confirmed for the total patient population, as well as for
each clinical subtype considered (PP and OF). The APOE
and SCA2 risk alleles were not over-represented in any of
the clinical subgroups of MS, in contrast to previous
studies by Hogh et al .,29 where a preferential representa-
tion of the APOE o4 allele was detected in patients with
the PP form.
This study included a correction for possible stratifica-
tion of the population, since controls were individually
matched to patients by gender, age and origin, whereas
other studies have used data from unmatched control
populations already described or randomly sel-
ected.28,29,31,32,3740 Population stratification can originate
false associations, which may explain the results pre-
viously obtained with the APOE o4 allele.29
In terms of MS severity and progression, no differences
were found in the PI or EDSS values between carriers and
noncarriers of o4 in our total sample. When we considered
patients with a disease duration less than 10 years (n/
69), however, we have detected an increased PI in carriers
Table 1 Demographic data and APOE and SCA2 genotypes among all MS cases
Demographic/clinical data Total APOE SCA2
o4/ o4/ P value 22/22/ 22/22/ P value
n 243 38 201 167 50
F/M (%) 70.0/30.0
Age (mean9/SD) 38.39/10.8
Age at onset (mean9/SD) 29.09/9.7 30.49/11.3 28.89/9.4 0.373a 8.59/9.2 31.19/9.6 0.103a
Disease duration (mean9/SD) 9.39/7.0 10.89/8.6 8.99/6.3 0.128a 9.29/7.0 9.49/6.4 0.883a
EDSS (n ; mean9/SD) 140b; 2.09/1.3 24; 2.09/1.1 114; 2.09/1.3 0.937a 103; 2.09/1.3 26; 1.99/1.0 0.794a
PI (n ; mean9/SD) 129b; 0.49/0.4 19; 0.49/0.5 108; 0.39/0.3 0.935c 95; 0.39/0.3 25; 0.39/0.4 0.936c
PI (n ; mean9/SD)
DD/10 years 60; 0.159/0.1 11; 0.139/0.09 47; 0.159/0.1 0.336c 45; 0.169/0.1 12; 0.139/0.04 0.876c
DDB/10 years 69; 0.529/0.4 8; 0.809/0.5 61; 0.499/0.4 0.026c 50; 0.499/0.4 13; 0.519/0.4 0.812c
n , number of cases; MS, multiple sclerosis patients; F, female; M, male; DD, disease duration.
a Students’s t -test.
b Total n is independent of APOE and SCA2 genotyping.
c Mann/Whitney test.
Table 2 Comparisons of genotype frequencies for APOE and
SCA2 genes between MS cases and controls
McNemar’s test Fisher’s exact
test
MS/HC PP/HC OF/HC PP/OF
APOE o4/ x2/0 x2/0.57 x2/0.46 P/0.26
P/1.00 PB/0.48 PB/0.53
SCA2 22/22/ x2/0.1 x2/0 x2/0.12 P/0.54
P/0.75 P/1.00 PB/0.75
Figure 1 Genotype frequencies for APOE and SCA2 loci. (a) APOE o4/ versus APOE o4/ genotype frequencies and (b) SCA2 22/22/
versus SCA2 22/22/ genotype frequencies, for both cases and controls. HC, healthy controls; MS, multiple sclerosis patients; PP,
primary progressive; OF, other forms of disease. Numbers at the top of columns are number of individuals with that genotype.
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of o4. A similar finding was described in Danish pa-
tients,29 and although this may be a spurious association
due to the greater instability that characterizes the initial
phase of the disease, when the EDSS evaluation is less
reliable, it may also be the reflection of a stronger effect of
the o4 allele in the earlier stages of the disease. ApoE is
known to play a role in the recapture of lipids from the
myelin of damaged neurones and this function may be of
particular relevance in the initial stages of MS pathogen-
esis. The role of the SCA2 22/22 genotype in MS
progression was excluded here, for the first time, when
we analysed the age at onset and severity parameters.
One of the questions that remains open in MS studies is
which instrument is the most appropriate to quantify
severity and rate of progression. The EDSS scale is non-
linear and can be equivocal, providing a mean value that
represents mostly the motor deficit; however, this is still
the most widely used scale for MS. Cognitive deficits, as
well as psychological and emotional dysfunction, may be
related with the risk alleles studied but have not been
assessed. In particular, it would be of great interest to
study this correlation with the APOE gene, given its
importance in the pathogenesis of dementia and the
recently proposed association of the AA genotype, at the
polymorphism -491 A/T in the promoter region of this
gene, with a higher risk of cognitive impairment in MS
patients.43 Severity of MS can also be studied through
MRI, measuring the load of cerebral lesions, which has
been described to be more aggressive in APOE o4 allele
carriers.30
In conclusion, the role of the SCA2 gene in MS has been
excluded in our population, whereas it remains possible
that the APOE gene may have role in the progression of
MS that is limited to the initial stages of the disease. This
question needs to be addressed in a larger sample of
patients with a short disease duration, using different
severity measures, before definite conclusions can be
drawn. To any extent, in our population, the association
between APOE and the disease course is too weak to be of
predictive value in the clinical practice.
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